Kezar Life Operating Income Over Time
| KZR Stock | USD 6.70 0.06 0.89% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Kezar Life Performance and Kezar Life Correlation. Can Biotechnology industry sustain growth momentum? Does Kezar have expansion opportunities? Factors like these will boost the valuation of Kezar Life. Expected growth trajectory for Kezar significantly influences the price investors are willing to assign. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Kezar Life demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
The market value of Kezar Life Sciences is measured differently than its book value, which is the value of Kezar that is recorded on the company's balance sheet. Investors also form their own opinion of Kezar Life's value that differs from its market value or its book value, called intrinsic value, which is Kezar Life's true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because Kezar Life's market value can be influenced by many factors that don't directly affect Kezar Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Kezar Life's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Kezar Life represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Kezar Life's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Operating Income Analysis
Compare Kezar Life Sciences and related stocks such as Creative Medical Tec, Aprea Therapeutics, and Adial Pharmaceuticals Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CELZ | (1.4 K) | (19.8 K) | (20.1 K) | (20.1 K) | (19.4 K) | (20.8 K) | (766.1 K) | (1.2 M) | (1.1 M) | (1.1 M) | (1.1 M) | (3.1 M) | (10.2 M) | (5.6 M) | (5.7 M) | (5.2 M) | (4.9 M) |
| APRE | (3.2 M) | (21.3 K) | (21.3 K) | (246.5 K) | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (16.5 M) | (29.5 M) | (52.8 M) | (37.4 M) | (113.4 M) | (15.5 M) | (14.3 M) | (12.9 M) | (13.5 M) |
| ADIL | (819.3 K) | (819.3 K) | (819.3 K) | (819.3 K) | (819.3 K) | (819.3 K) | (410.8 K) | (995.3 K) | (7 M) | (8.2 M) | (10.9 M) | (19.3 M) | (10.9 M) | (6.9 M) | (8.3 M) | (7.5 M) | (7.8 M) |
| KPRX | (5.9 M) | (5.9 M) | (5.9 M) | (3.1 M) | (2.5 M) | (6.7 M) | (13.3 M) | (14.6 M) | (10.8 M) | (7 M) | (6.9 M) | (14.2 M) | (12.3 M) | (12.6 M) | 4.5 M | 4.1 M | 4.3 M |
| CDIO | (609.2 K) | (609.2 K) | (609.2 K) | (609.2 K) | (609.2 K) | (609.2 K) | (609.2 K) | (609.2 K) | (609.2 K) | (609.2 K) | (609.2 K) | (620.4 K) | (4.5 M) | (7.2 M) | (8.4 M) | (7.5 M) | (7.2 M) |
| PHIO | (12.8 M) | (12.8 M) | (13 M) | (20.9 M) | (8.8 M) | (10.2 M) | (9 M) | (14.1 M) | (7.4 M) | (9 M) | (8.8 M) | (13.5 M) | (11.5 M) | (10.8 M) | (7.4 M) | (8.5 M) | (8.9 M) |
Kezar Life Sciences and related stocks such as Creative Medical Tec, Aprea Therapeutics, and Adial Pharmaceuticals Operating Income description
Operating Income is the amount of profit realized from Kezar Life Sciences operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Kezar Life Sciences is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Kezar Life Sciences | KZR |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 4000 Shoreline Court, |
| Exchange | NASDAQ Exchange |
USD 6.7
Additional Tools for Kezar Stock Analysis
When running Kezar Life's price analysis, check to measure Kezar Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kezar Life is operating at the current time. Most of Kezar Life's value examination focuses on studying past and present price action to predict the probability of Kezar Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kezar Life's price. Additionally, you may evaluate how the addition of Kezar Life to your portfolios can decrease your overall portfolio volatility.